Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
15 09 2020
Historique:
pubmed: 8 9 2020
medline: 12 3 2021
entrez: 7 9 2020
Statut: ppublish

Résumé

Background Early reduction in albuminuria with an SGLT2 (sodium-glucose cotransporter 2) inhibitor may be a positive indicator of long-term cardiovascular and renal benefits. We assessed changes in albuminuria during the first 12 weeks of treatment and subsequent long-term cardiovascular and renal risks associated with the SGLT2 inhibitor, empagliflozin, in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) trial. Methods and Results We calculated the percentage urinary albumin creatinine ratio (UACR) change from baseline to week 12 in 6820 participants who did not experience a cardiovascular outcome (including 3-point major cardiovascular events and cardiovascular death or hospitalization for heart failure) or renal outcome (defined as 40% decline in estimated glomerular filtration rate from baseline, estimated glomerular filtration rate <15 mL/min per 1.73 m

Identifiants

pubmed: 32893717
doi: 10.1161/JAHA.120.016976
pmc: PMC7727012
doi:

Substances chimiques

Benzhydryl Compounds 0
Glucosides 0
Sodium-Glucose Transporter 2 Inhibitors 0
empagliflozin HDC1R2M35U

Banques de données

ClinicalTrials.gov
['NCT01131676']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e016976

Références

Curr Diab Rep. 2018 Mar 27;18(5):27
pubmed: 29589183
JAMA Cardiol. 2018 Feb 1;3(2):155-163
pubmed: 29214305
Diabetes Care. 2019 Oct;42(10):1921-1929
pubmed: 31371432
Clin J Am Soc Nephrol. 2015 Mar 6;10(3):410-6
pubmed: 25568217
Kidney Int. 2004 Jun;65(6):2309-20
pubmed: 15149345
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
J Am Heart Assoc. 2020 Sep 15;9(18):e016976
pubmed: 32893717
Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139
pubmed: 30635226
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Lancet Diabetes Endocrinol. 2014 May;2(5):369-84
pubmed: 24795251
J Am Soc Nephrol. 2009 Aug;20(8):1813-21
pubmed: 19443635
Curr Treat Options Cardiovasc Med. 2017 Mar;19(3):23
pubmed: 28299616
Am J Kidney Dis. 2014 Dec;64(6):848-59
pubmed: 25441438
Clin Kidney J. 2018 Dec;11(6):749-761
pubmed: 30524708
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Diabetes Obes Metab. 2016 Feb;18(2):169-77
pubmed: 26511599
J Am Board Fam Med. 2016 Sep-Oct;29(5):604-12
pubmed: 27613793
BMC Nephrol. 2017 Apr 12;18(1):132
pubmed: 28399844
Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621
pubmed: 28666775
Lancet. 1990 Mar 31;335(8692):765-74
pubmed: 1969518
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes Care. 2018 Jan;41(1):163-170
pubmed: 29079715
Am J Kidney Dis. 2013 May;61(5):716-22
pubmed: 23337799
Kidney Int. 2014 Jul;86(1):40-9
pubmed: 24759154
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127
pubmed: 30635225
Eur Heart J. 2013 May;34(19):1424-31
pubmed: 23470495
Cardiovasc Diabetol. 2018 Nov 28;17(1):150
pubmed: 30486889
Cardiovasc Diabetol. 2014 Jun 19;13:102
pubmed: 24943000
Diabetes Obes Metab. 2012 Jan;14(1):83-90
pubmed: 21985634
Kidney Int. 2007 Jul;72(1):92-9
pubmed: 17440495
J Am Soc Nephrol. 2009 Feb;20(2):436-43
pubmed: 19092125
Kidney Int. 2003 Jun;63(6):2254-61
pubmed: 12753315
Kidney Int Rep. 2018 Apr 16;3(4):939-949
pubmed: 29988998
JAMA. 2015 Jul 7;314(1):52-60
pubmed: 26151266
JACC Heart Fail. 2019 May;7(5):394-401
pubmed: 31047019
Lancet. 2012 Nov 10;380(9854):1662-73
pubmed: 23013602
Am J Kidney Dis. 2005 Feb;45(2):281-7
pubmed: 15685505
Clin Kidney J. 2016 Jun;9(3):432-7
pubmed: 27274830
J Am Soc Nephrol. 2018 Aug;29(8):2225-2233
pubmed: 29930161
Arch Intern Med. 2005 Apr 25;165(8):947-53
pubmed: 15851648
Diabetes Obes Metab. 2013 Jul;15(7):613-21
pubmed: 23356556

Auteurs

Simke W Waijer (SW)

Department of Clinical Pharmacy and Pharmacology University of GroningenUniversity Medical Center Groningen Groningen the Netherlands.

Di Xie (D)

Department of Clinical Pharmacy and Pharmacology University of GroningenUniversity Medical Center Groningen Groningen the Netherlands.
National Clinical Research Center for Kidney Disease Nanfang Hospital Guangzhou China.

Silvio E Inzucchi (SE)

Section of Endocrinology Yale University School of Medicine New Haven CT.

Bernard Zinman (B)

Lunenfeld-Tanenbaum Research InstituteMt Sinai HospitalUniversity of Toronto Ontario Canada.

Audrey Koitka-Weber (A)

Boehringer Ingelheim International GmbH Ingelheim Germany.
Department of Medicine Division of Nephrology Würzburg University Clinic Würzburg Germany.
Department of Diabetes Central Clinical School Monash University Melbourne Australia.

Michaela Mattheus (M)

Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany.

Maximillian von Eynatten (M)

Boehringer Ingelheim International GmbH Ingelheim Germany.

Lesley A Inker (LA)

Tufts University School of MedicineTufts Medical Center Boston MA.

Christoph Wanner (C)

Department of Medicine Division of Nephrology Würzburg University Clinic Würzburg Germany.

Hiddo J L Heerspink (HJL)

Department of Clinical Pharmacy and Pharmacology University of GroningenUniversity Medical Center Groningen Groningen the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH